By depleting PTG, an activator of the glycogen chain-elongating enzyme glycogen synthase (GYS1), in laforin- and malin-deficient LD mice, we show that abnormal glycogen chain lengths and not ...

In a notable study, researchers designed and synthesized novel compounds that act as dual inhibitors targeting both glutaminyl cyclase and glycogen synthase kinase-3β (GSK-3β), another enzyme ...

Glycogen phosphorylase (GP ... Recent studies have focused on identifying and developing various GP inhibitors, exploring their potential benefits not only for diabetes management but also ...

Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

Hypertension is a major global health issue. Aldosterone synthase inhibitors (ASIs) have emerged as a promising therapeutic strategy for blood pressure control. A thorough search of the MEDLINE and ...